IDiyas

For the Inventor, By the Inventor

Jefferson, MD, United States of America

Rodger G Smith

USPTO Granted Patents = 14 

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 174(Granted Patents)


Location History:

  • Rockville, MD (US) (2012 - 2014)
  • Jefferson, MD (US) (1997 - 2016)

Company Filing History:

goldMedal5 out of 6 
 
Teva Biopharmaceuticals Usa, Inc.
 patents
silverMedal5 out of 57 
 
Igen International, Inc.
 patents
bronzeMedal2 out of 50 
 
Igen, Inc.
 patents
4. 1 out of 15 
 
Bioveris Corporation
 patents
5. 1 out of 832,718 
Other
 patents

Years Active: 1997-2016

Loading Chart...
14 patents (USPTO):Explore Patents
1. 9416185 - Humanized antibodies against TL1A (2016-08-16),
2. 8728482 - Humanized antibodies against TL1A (2014-05-20),
3. 8524869 - Humanized antibodies against LIGHT and uses thereof (2013-09-03),
4. 8435522 - Humanized antibodies against CXCR3 (2013-05-07),
5. 8263743 - Humanized antibodies against TL1A (2012-09-11),
6. 6890712 - Cycling DNA/RNA amplification electrochemiluminescent probe assay (2005-05-10),
7. 6702705 - Prodrugs activated by targeted catalytic proteins (2004-03-09),
8. 6258360 - Prodrugs activated by targeted catalytic proteins (2001-07-10),
9. 6177270 - Reaction-based selection for expression of and concentration of catalytic moieties (2001-01-23),
10. 6121007 - Reaction-based selection for expression of and concentration of (2000-09-19),
11. 6048687 - Cycling DNA/RNA amplification electrochemiluminescent probe assay (2000-04-11),
12. 5891648 - Reaction-based selection for expression of and concentration of (1999-04-06),
13. 5855885 - Isolation and production of catalytic antibodies using phage technology (1999-01-05),
14. 5631137 - Reaction-based selection for expression of and concentration of (1997-05-20),

Title: Inventor Spotlight: Rodger G. Smith

Introduction

Rodger G. Smith is a prolific inventor based in Jefferson, Maryland, known for his significant contributions to the field of biopharmaceuticals. With a remarkable portfolio consisting of 14 patents, his innovative work focuses primarily on humanized antibodies, which have the potential to lead to advancements in medical treatments.

Latest Patents

Among his latest patents are humanized antibodies against TL1A. These antibodies are noteworthy for their specificity to TNF superfamily member 15 (TNFSF15), commonly recognized as TL1A. The disclosed patents detail methods for creating and utilizing these anti-TL1A antibodies. These humanized antibodies may function as antagonists and possess the capacity to both treat and diagnose disorders linked to TL1A function.

Career Highlights

Throughout his career, Rodger G. Smith has made significant strides in the biopharmaceutical industry. He has worked with notable companies, including Teva Biopharmaceuticals USA, Inc. and Igen International, Inc., where he honed his expertise in the field of antibody development and therapeutic innovation.

Collaborations

Rodger has collaborated with distinguished coworkers Mark T. Martin and David M. Simpson, contributing to various projects that have furthered advancements in biotherapeutics. These collaborations illustrate the teamwork and collective expertise required to push the boundaries of innovation in the pharmaceutical sector.

Conclusion

Rodger G. Smith continues to be a key figure in the biopharmaceutical landscape. With his extensive patent portfolio and collaborative spirit, he remains dedicated to pioneering solutions that address pressing medical challenges. His work exemplifies the importance of innovation in healthcare, potentially leading to new therapies that improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…